Updated analysis of the STAMPEDE trial found no benefit for zoledronic acid in reducing deaths or skeletal-related events and confirmed the overall survival benefit of docetaxel in men with advanced hormone-sensitive prostate cancer.

MDV3100, in advanced triple-negative breast cancer, found a therapeutic benefit with enzalutamide in patients expressing the androgen receptor. Median overall survival was 12 months, extended to 18 months for patients with a favorable genetic profile, according to the PREDICT AR assay.

In patients with early melanoma, restricting the time interval between primary surgical excision and sentinel node biopsy to less than 6 weeks does not appear to be necessary. Patients had similar survival outcomes at any cutoff interval from 1 to 8 weeks.

In patients with advanced melanoma, the sequence of checkpoint inhibitors may matter. Nivolumab (Opdivo) followed by ipilimumab (Yervoy) may be more efficacious, but it is also more toxic than the opposite sequence.

Investigators evaluating PD-L2 as a potential biomarker for response to pembrolizumab (Keytruda) found that approximately two-thirds of all tumors scored PD-L2–positive, and response rates were twice as high if tumors were positive for both PD-L1 and PD-L2 expression.

The IMA901 multipeptide vaccine failed to improve overall survival when combined with sunitinib vs sunitinib alone in patients with metastatic renal cell carcinoma in an open-label phase III trial.

In an analysis of survival after a diagnosis of gastrointestinal cancer (not just colorectal cancer), 5-year survival was higher in patients who used aspirin postdiagnosis—75% vs 42% among nonusers. ■